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ABSTRACT: Hormonal steroids participate in the
control of a large number of functions of the central
nervous system (CNS); recent data show that they may
also intervene at the level of the peripheral nervous
system (PNS). Both the CNS and the PNS metabolize
endogenous as well as exogenous steroids; one of the
major enzymatic system is represented by the 5a-reduc-
tase-3a–hydroxysteroid complex. This is a versatile sys-
tem, since every steroid possessing the delta 4-3keto
configuration (e.g., testosterone, progesterone, deoxy-
corticosterone) may be a substrate. High levels of 5a-
reductase are found in the white matter of the CNS and
in purified myelin. The observation that, in addition to
neurons, glia may be a target for steroid action is an
important recent finding. The effects of progesterone,
testosterone, corticoids, and their respective 5a and
3a-5a derivatives on the expression of glial genes are
presented and discussed. It has also been found that
progesterone and/or its 5a-reduced metabolites increase
the mRNA for the two major proteins of peripheral
myelin, the glycoprotein Po and the peripheral myelin
protein 22, in the sciatic nerve of normal and aged
animals and in Schwann cells. The hypothesis has been
put forward that glycoprotein Po might be under the
control of progestagens acting mainly via the progester-
one receptor, and that peripheral myelin protein 22
might be controlled via an interaction of steroids with
the g-aminobutyric acid (GABA)ergic system. It is
known that tetrahydroprogesterone, the 3a-5a–reduced
metabolite of progesterone, interacts with the GABAA
receptor. Our recent data show that several subunits of
this receptor are present in sciatic nerve as well as in
Schwann cells that reside in this nerve. These data open
multiple possibilities for new therapeutic approaches to
demyelinating diseases. © 1999 John Wiley & Sons, Inc. J Neu-
robiol 40: 471–483, 1999
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INTRODUCTION
Hormonal steroids participate in the control of a large
number of brain functions during the fetal and neo-
natal period, when they act to organize the nervous
system, as well as during adulthood, when they act to
regulate several physiological functions. Hormonal
steroids may also intervene in the process of aging in
the central nervous system (CNS), especially in some
specific structures (e.g., the hippocampus). Classical
intracellular receptors for each family of hormonal
steroids are present in many CNS structures. Some
families of receptors are preponderant in some partic-
ular brain areas. For instance, glucocorticoid receptors
(GR) and minerocorticosteroid receptors (MR) prevail
in the limbic system, while the receptors for sex
hormones [androgen receptors (AR), estrogen recep-
tors (ERa and b), and progesterone receptors (PR)]
have a more generalized distribution, although higher
concentrations are seen in the hypothalamus and
amygdala (McEwen, 1991, 1994). It is important to
note that the presence of receptors for hormonal ste-
roids is not limited to neurons, but that these are also
found in glial elements (e.g., astrocytes and oligoden-
drocytes) (Vielkind et al., 1990; Jung-Testas et al.,
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1992, 1994; Langub and Watson, 1992; Wolff et al.,
1992). Steroid receptors in both neurons and glia
undoubtedly have important physiological implica-
tions because of the close cross-talk existing between
neurons and glial cells (see below). One important
observation is that the brain may metabolize endoge-
nous and exogenous steroids. Several enzymatic sys-
tems have been described, and some of them have
been fully characterized (for review, see Celotti et al.,
1992; Martini, 1982). Among these, some have the
peculiarity of totally changing the endocrine profile of
a given steroid [e.g., aromatization of testosterone (T)
to estradiol (E)], while others have the property of
enhancing its activity [e.g., 5a-reductase (5a-R)
which converts T to dihydrotestosterone (DHT)];
moreover, some enzymes (e.g., 3a-hydroxysteroid de-
hydrogenase, 3a-HSD) modify steroids so that their
metabolites may interact with receptors other than the
classical steroid receptors. As detailed below, the
enzymes 5a-R and 3a-HSD are present in neurons
and glia (Melcangi et al., 1990a, 1993, 1994a).
More recent evidence also indicates that the pe-
ripheral nervous system (PNS), and particularly the
Schwann cells (which are the equivalent in the pe-
riphery to the glia elements present in the CNS),
which may be sensitive to steroid effects, possess
steroid receptors (Jung-Testas et al., 1996; Melcangi
et al., 1998a; Magnaghi et al., 1999) and the enzymes
for steroid metabolism (Melcangi et al., 1990b, 1992).
Some data suggest that the PNS and Schwann cells
may also be the site of synthesis for some hormonal
steroids (Koenig et al., 1995). The enzymatic complex
formed by 5a-R and 3a-HSD in the CNS (for review,
see Celotti et al., 1992; Martini, 1982) is very versa-
tile in the sense that every steroid possessing the delta
4-3keto configuration may be first 5a-reduced and
subsequently 3a-hydroxylated. For instance, T can be
converted into DHT and subsequently into 5a-andro-
stane-3a,17b-diol (3a-diol); progesterone (P) can be
metabolized into dihydroprogesterone (DHP) and sub-
sequently into 3a,5a-tetrahydroprogesterone (THP);
corticosterone into dihydrocorticosterone (DHC); and
finally, deoxycorticosterone (DOC) into 5a-dihydro-
deoxycorticosterone (DHDOC) and 3a,5a-tetrahy-
drodeoxycorticosterone (THDOC). As detailed be-
low, some 5a-reduced-3a-hydroxysteroids may exert
important biological activities with a mechanism dif-
ferent from that of the parent steroids.
The existence of more than one 5a-R isozyme had
been postulated years ago on the basis of studies using
various inhibitors (Motta et al., 1986; Zoppi et al.,
1992) and different substrates (Motta et al., 1986).
More recently, two isoforms of the 5a-R (types 1 and
2) have been cloned (Andersson et al., 1989, 1991;
Labrie et al., 1992; Normington and Russell, 1992;
Russell and Wilson, 1994; Levy et al., 1995). In men,
the type 1 5a-R gene, on chromosome 5, is composed
of five exons and four introns and produces a protein
of 259 amino acids. The type 2 5a-R gene, located on
chromosome 2, has a similar structure, but the result-
ing protein is composed of 254 amino acids. The
structures of the enzymatic proteins, determined from
their respective cDNAs, show a limited degree of
homology (about 47%), and a predicted molecular
weight of 28–29 kD. In terms of primary structures,
both isozymes are composed of a high number of
hydrophobic amino acid residues distributed through-
out the molecule, causing the enzymes to be located in
intracellular membranes. Although the two isoforms
of the 5a-R (types 1 and 2) catalyze the same reaction
(e.g., T to DHT, P to DHP), they possess different
biochemical and possibly functional properties. The
affinity of T for the type 1 isoform is about 15- to
20-fold lower than that for the type 2 isoform. The
two isoforms have a different pH optimum: the type 1
isoform is active in a wide range of pH (from 5 to 8),
while the type 2 5a-R possesses a narrow pH opti-
mum around 5, with a very low activity at pH 7.5. The
two isozymes also show a differential sensitivity to
synthetic inhibitors such as finasteride, which prefer-
entially blocks the human type 2 isozyme (Thigpen
and Russell, 1992). High levels of 5a-R are observed
in CNS areas particularly rich in white matter, such as
the midbrain (Snipes and Shore, 1982), the pons
(Krieger et al. 1983), the spinal cord (MacLusky et al.,
1987), the corpus callosum, the anterior commissure,
and the optic chiasm (Melcangi et al., 1988a, 1989).
Also, the formation of 3a-diol is significantly higher
in white-matter structures than in the gray matter
(Melcangi et al. 1988a, 1988b). The 5a-R, but not the
3a-HSD, is present in elevated concentrations in pu-
rified myelin preparations obtained from the rat brain
(Melcangi et al. 1988a,b, 1989). The physiological
meaning of this localization of 5a-R is still obscure,
but the hypothesis that 5a-reduced steroids locally
formed in myelin might play a role in the process of
myelination is certainly attractive. Such an hypothesis
is indirectly supported by data showing that there is a
peak of 5a-R activity in rat CNS (Massa et al., 1975;
Degtiar et al., 1981) and in the purified CNS myelin in
the first weeks of life (Melcangi et al., 1988b), the
time when myelinization is initiated (Norton and Po-
duslo, 1973). Moreover, the cells which manufacture
myelin, the oligodendrocytes, possess some 5a-R ac-
tivity (Melcangi et al., 1988b, 1993, 1994a).
Data on the distribution of the 5a-R in different
cell types in the rat brain show that neurons possess
significantly higher amounts of 5a-R activity than
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oligodendrocytes and astrocytes (Melcangi et al.,
1993, 1994a). In cultures of rat brain cells, two dis-
tinct populations of astrocytes may be distinguished
on morphological and antigenic bases, the so-called
type 1 and type 2 astrocytes. Type 1 astrocytes show
a fibroblast-like aspect and are positive for the pres-
ence of the glial fibrillary acidic protein (GFAP) and
negative to an antibody (A2B5) direct against the
membrane gangliosides GD1b, GT1, and GQ. Type 2
astrocytes have a process-bearing morphology, re-
sembling that of neurons or oligodendrocytes, and are
positive for both GFAP and the A2B5 antibody.
Among these glial cells, the type 2 astrocytes possess
considerable 5a-R activity, while type 1 astrocytes
(A1) are almost devoid of such activity. Surprisingly,
the enzyme 3a-HSD appears to be mainly localized in
A1 (Melcangi et al., 1993, 1994a), with very low
levels in other glial elements and in neurons. These
data suggest that neurons and glial cells can both
participate in the 5a-reductive metabolism of T and
other delta 4-3 keto steroids. It must be pointed out
that neurons are the only cell population which, in
addition to the 5a-R, also contain the enzyme aro-
matase and consequently are able to transform andro-
gens into estrogens (Negri-Cesi et al., 1992). Interest-
ingly, very recently Garcia-Segura et al. (1999)
observed that aromatase is expressed also in astro-
cytes after brain injury. As previously mentioned,
3a-HSD may be considered the second element of the
5a-R system. The formation of 3a-hydroxylated 5a-
reduced derivatives may subserve different physiolog-
ical roles; this reaction may be of importance (a) for
decreasing the amounts of intracellular 5a-reduced
compounds available for binding to the corresponding
intracellular steroid receptors, or (b) for producing
steroid derivatives which may act through non-
genomic mechanisms (e.g., via the GABAA receptor;
see below).
EFFECT OF HORMONAL STEROIDS
ON GLIAL CELLS OF THE CNS
Progesterone and Androgens
The cytoskeletal protein GFAP, a component of the
intermediate glial filaments, is considered an impor-
tant and specific astrocytic marker, since it is found
only in astrocytes and radial glia. This protein is
involved in modulating astrocyte shape and motility
(Laping et al., 1994). Recent data have shown that
GFAP may be under the control of a wide variety of
humoral principles which include cytokines, growth
factors, and hormonal steroids (Laping et al., 1994;
for review, see Garcia-Segura et al., 1996). In this
context, it has been shown that in vivo treatment with
corticosterone and other corticoids (e.g., dexametha-
sone) inhibits GFAP expression in the neonatal and
adult rat brain (Laping et al., 1991; Nichols et al.,
1990a,b; Tsuneishi et al., 1991). In contrast, cortico-
sterone increases GFAP expression in cultured astro-
cytes (Rozovsky et al., 1995); this result suggests that
the effects observed in vivo are indirect and possibly
mediated via nearby neurons or other glial elements
(Rozovsky et al., 1995). With regard to sex steroids,
castration of male rats increases the levels of GFAP
mRNA and protein in the hippocampus (Day et al.,
1990, 1993). It is interesting that among the gonadal
steroids tested (estradiol, T, and DHT), only estradiol
proved able to counteract the effect of castration (Day
et al., 1993). At variance with what happens in the
hippocampus, castration decreases GFAP immunore-
activity in the hypothalamus, a phenomenon that
seems to be counteracted by T and DHT, but not by
estradiol (Day et al., 1993). Interesting relationships
between androgens and astrocytic function also
emerge from the observations that hypothalamic as-
trocytes exhibit an increased in GFAP immunoreac-
tivity in androgen-insensitive testicular feminized
mice (McQueen et al., 1990), and that hypothalamic
and hippocampal astrocytes show an increased GFAP
immunoreactivity in hypogonadal mice (hpg) (Mc-
Queen, 1994). Surprisingly, in hpg mice, which pos-
sesses normal sex hormone receptors, estrogens and
aromatizable androgens, but not DHT, are able to
normalize hippocampal GFAP immunoreactivity
without altering that of the hypothalamus. After a
penetrating brain injury, sex steroids (estradiol and P
in females, and T in males) are able to decrease gliosis
(including astrocytic proliferation), resulting in a de-
crease in the number of GFAP-positive astrocytes in
the lesioned area (Garcia-Estrada et al., 1993). In the
arcuate nucleus and the hilus of the dentate gyrus of
adult female rats, the surface density of GFAP-immu-
noreactive cells fluctuates throughout the estrous cy-
cle (Garcia-Segura et al., 1994a,b, 1996), decreases
after ovariectomy, and increases after the administra-
tion of either estradiol or P (Luquin et al., 1993).
Recently, it has also been observed that the levels of
GFAP mRNA and immunoreactivity show sex differ-
ences in the arcuate nucleus of the rat, with lower
levels in females than in males (Chowen et al., 1995).
Androgenization of neonatal females increases GFAP
mRNA to male levels, while castration of newborn
males, without T substitution, reduces GFAP mRNA
to the levels found in females (Chowen et al., 1995).
Taken together, these data point to a possible influ-
ence of sex steroids on the expression and synthesis of
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GFAP. However, the data collected so far do not
address the question of whether sex hormones act
directly on the astrocytes to exert these influences.
A systematic study of the effects of sex steroids
and their metabolites on the expression of GFAP in
astrocytic cultures was recently performed in the au-
thors’ laboratory. This study analyzed the effects ex-
erted by P and T and by their respective 5a-reduced
metabolites (DHP and THP, and DHT and 3a-diol) on
type 1 astrocytes (Melcangi et al., 1996a). The cul-
tures were exposed to the various steroids for 2, 6, and
24 h, and GFAP mRNA was measured by Northern
blot analysis. A significant elevation in GFAP mRNA
was observed after exposure to either P or DHP; the
effect of DHP appeared more promptly (2 h) than that
of P (6 h). This result suggests that the effect of P
might be linked to its conversion into DHP; this
hypothesis has been confirmed by showing that the
addition of finasteride (a blocker of the 5a-R) is able
to completely abolish the effect of P. At late intervals,
exposure to DHP caused a decrease rather than an
increase in GFAP gene expression (Melcangi et al.,
1996a). This inhibitory effect appears similar to the
one evoked by direct exposure to THP; consequently,
THP may be the active metabolite exerting an inhib-
itory effect on GFAP mRNA. This is supported by the
observation that type 1 astrocytes are extremely rich
in the enzyme 3a-HSD, which converts DHP into
THP (Melcangi et al., 1994a). Thus, the biphasic
effect of DHP (stimulatory at earlier intervals and
inhibitory at later times) may be related to the sequen-
tial conversion of P into its related metabolites DHP
and THP; because of this differential intracellular
signaling pathways are probably involved. P and DHP
may bind to their specific intracellular receptors
present in the astrocytes (Jung-Testas et al., 1992). In
this context, it is important to recall that P and DHP
bind to the intracellular P receptor (Lee et al., 1979;
Rupprecht et al., 1993; Schenborn and Karavolas,
1983), while THP does not. Some steroids, and in
particular 3a-hydroxy-5a-reduced pregnane deriva-
tives, are potent ligands for the GABAA receptor in
the CNS (Majewska et al., 1986; Paul and Purdy,
1992; Puia et al., 1990). On the basis of these obser-
vations, it is possible that the inhibitory effect exerted
by THP (and probably by DHP after its conversion
into THP) on GFAP expression might be mediated by
the activation of GABAA receptors.
In the case of androgens, T and 3a-diol did not
change GFAP expression at any time of exposure,
while DHT produced a significant decrease of GFAP
mRNA only after 24 h (Melcangi et al., 1996a). This
study should be completed using synthetic androgenic
compounds which do not undergo metabolic conver-
sions, but which do bind to and activate the AR, like
T and DHT. All these new findings indicate that sex
steroids may act directly on astrocytes.
Glucocorticoids and Minerocorticoids
Because of their antiinflammatory and antiimmune
properties, glucocorticoids are one of the major ther-
apeutic options for the treatment of multiple sclerosis
and other demyelinating diseases. However, little and
conflicting information is available on the direct ef-
fects that corticoids might exert on the oligodendro-
cytes (i.e., the myelin-producing cells), on other kinds
of glial cells, and on myelin components, e.g., the
myelin basic protein (MBP), in the CNS (Meyer and
Fairman, 1985; Preston and McMorris, 1984; Tsunei-
shi et al., 1991). Because of this, our laboratory ex-
amined the effects of different types of glucocorti-
coids and minerocorticoids on MBP expression using
oligodendrocyte cultures. Moreover, on the basis of
the presence of the enzyme 5a-R and 3a-HSD in
these cells (Melcangi et al., 1990a, 1993, 1994a) the
effect of the 5a-reduced metabolites was also exam-
ined. Among the different steroids tested (corticoste-
rone, DHC, DOC, DHDOC, and THDOC), only DH-
DOC was effective in modifying MBP gene
expression in cultures of oligodendrocytes; mRNA
levels of this typical oligodendrocyte marker were
decreased following exposure to this steroid for 24 h
(Melcangi et al., 1997a). To our knowledge, this is the
first demonstration that adrenal steroids in their native
or 5a-reduced forms modify MBP gene expression in
oligodendrocyte cultures. The efficacy of steroids on
this parameter has so far been shown only from in
vivo studies (Tsuneishi et al., 1991). The finding that
DHDOC is able to modify MBP gene expression
necessitates a few comments. First, it is important to
point out that the mode of action of this steroid on
MBP mRNA is not yet clear. No studies are available
to indicate whether DHDOC binds and activates the
GR and/or the MR. The fact that the other steroids
tested, which are able to bind to the GR and MR, are
inactive would tend to eliminate the possibility of an
effect of DHDOC via those receptors. DHDOC has,
however, been shown to bind to and activate the PR
(Tsuneishi et al., 1991; Rupprecht 1996). Consistent
with this is the fact that DHDOC, like progesterone,
exerts antiminerocorticoid activity (Sekihara and
Yazaki, 1993). It is thus possible that the effects of
this steroid on MBP gene expression may be mediated
via the PR, a receptor that is present in oligodendro-
cytes (Jung-Testas et al., 1992, 1994). The physiolog-
ical meaning of these results is still unclear. However,
it is important to recall once more that 5a-R activity
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present in oligodendrocytes (Melcangi et al., 1988b,
1993, 1994a) varies across the different phases of
myelinization (Melcangi et al., 1988b).
Corticoids also appear able to control the synthesis
and expression of specific astrocytic markers. How-
ever, the data are difficult to interpret since various
types of steroids with different specific activities and
with different glucocorticoid versus minerocorticoid
ratios have been used. Moreover, the administration
schedules and times of observation also have been
very variable. For instance, in vivo treatment with
dexamethasone, performed in the neonatal rat, signif-
icantly diminishes GFAP gene expression (Tsuneishi
et al., 1991). Corticosterone administrated in vivo to
neonatal or adult rats also inhibits GFAP gene expres-
sion and synthesis (Tsuneishi et al., 1991, Laping et
al., 1991, 1994; Nichols et al., 1990a,b; O’Callaghan
et al., 1989). In line with this observation, adrenalec-
tomy performed in adult rats has been shown to in-
crease GFAP mRNA and protein, an effect which is
reversed by corticosterone administration (Laping et
al., 1994). However, a different pattern of activity is
shown by corticosterone in vitro, since exposure of
cultured astrocytes to this steroid induces an increase
in GFAP mRNA and protein (Rozovsky et al., 1995).
Surprisingly, this effect of corticosterone on GFAP is
reversed if astrocytes are cocultured with neurons, a
finding which suggests that there is cross-talk between
the two types of cells, and provides a possible expla-
nation for the discrepancies between results obtained
in vivo and in vitro (Rozovsky et al., 1995). Because
of this, a study similar to that previously described for
MBP was performed using astrocytic cultures. GFAP
mRNA was increased by exposure to corticosterone
for 6 and 24 h, while DHC was ineffective. The
minerocorticoid DOC was also ineffective, while its
5a-reduced derivative, DHDOC, strongly inhibited
GFAP gene expression (Melcangi et al., 1997a). The
observation that corticosterone increases GFAP gene
expression in A1 in cultures is not surprising, since
similar data were reported by Rozovsky et al. (1995)
using a similar experimental protocol. The present
data suggest in addition that this effect is probably not
linked to the 5a-reduction of the steroid, since the
effect of corticosterone is not duplicated by DHC, a
steroid that was not included in the study of Rozovsky
et al. (1995). It is interesting to note that the stimula-
tory effect of corticosterone, a steroid with mixed
glucominerocorticoid activities, on GFAP expression
are not duplicated by the pure minerocorticoid deriv-
ative used. This fact suggests that the effect observed
may be due to the glucocorticoid rather than minero-
corticoid properties of corticosterone. This hypothesis
obviously needs confirmation in studies with a “pure”
GR agonist. It is relevant to the present discussion to
recall that the synthesis of GFAP may represent an
early response of astrocytes and microglia to brain
injury and lesioning (Laping et al., 1994). Conse-
quently, one might extrapolate from the present data
that stress might influence GFAP synthesis also via
the activation of the adrenal cortex.
The present data have shown that at least one
5a-reduced metabolite of adrenal steroids (DHDOC)
exerts a similar effect on MBP gene expression in
oligodendrocytes and GFAP gene expression in astro-
cytes, with a decrease of their mRNA levels. Even if
DHDOC is converted into THDOC, the GABAA re-
ceptor does not appear to be involved since THDOC,
which interacts with the GABAA receptor (Rupprecht
et al., 1996, 1993), is totally ineffective in regulating
either MBP or GFAP gene expression.
GLIAL–NEURONAL INTERACTIONS IN
THE CNS
For many years, glial cells have been considered to
represent only mechanical support for neurons. This
concept is obviously no longer acceptable. The exis-
tence of important functional relationships between
specific glial components (oligodendrocytes, astro-
cytes, etc.) and neurons have become apparent. The
interaction of glial cells with neurons plays an impor-
tant role in neuronal migration, neurite outgrowth, and
axonal guidance during neural development (Rakic,
1971; Banker, 1980; Lindsay, 1987; Hatten et al.,
1988; Gasser and Hatten, 1990). Moreover, it has
recently been demonstrated that glial cells synthesize
and possibly release an array of bioactive agents such
as neurotransmitters, growth factors, interleukines,
prostaglandins, excitatory amino acids, polyamines,
and neurosteroids (for review, see LoPachin and As-
chner, 1993). It is likely that several of these agents
exert definite and specific influences on neuronal ac-
tivity. On the other hand, glial–neuronal interactions
are certainly not one-way, since neurons can interfere
with the proliferation and maturation of glial ele-
ments. For example, neuronal activity has been shown
to up-regulate the expression of GFAP (Steward et al.,
1991). Moreover, other parameters of astrocytic func-
tion, such as the enzyme glutamine synthetase
(Mearow et al., 1990), the formation of gangliosides
(Mendez-Otero and Constantine-Paton, 1990), and the
assembly of voltage-sensitive calcium channels (Cor-
valan et al., 1990), are activated only in the presence
of neurons. Thus, the concept has emerged that neu-
rons and glia (astrocytes type 1 and 2, oligodendro-
cytes), in the CNS form a functional unit in which
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each single element exerts effects on the other. As it
has been previously mentioned, the enzyme 5a-R is
present both in neurons (where it shows its higher
concentrations) and in the glia (Melcangi et al., 1993,
1994a), while the enzyme 3a-HSD is almost exclu-
sively present in A1 (Melcangi et al., 1993, 1994a).
The cellular localization of these two enzymes in the
brain has prompted us to investigate whether neurons
and glial cells interact via humoral messages to con-
trol these two enzymes.
Two approaches have been used to examine the
interactions between A1 and neurons: (a) a coculture
system in which the two types of cells remain phys-
ically separated but which allows the free transfer of
secretory products from one to the other type of
cocultured cells, and (b) the addition of neuron-con-
ditioned medium (CM) to cultures of A1, and astro-
cytic CM to cultures of neurons. The data have con-
sistently shown that coculture with neurons or
exposure to the neuronal CM stimulates 5a-R and
3a-HSD activities in A1. In contrast, there was no
effect of astrocyte secretory products on the enzy-
matic activity of neurons (Melcangi et al., 1994b,
1995a). It appears that one or more soluble substanc-
e(s) are secreted by neurons which are able to stimu-
late the two enzymes in A1. Experiments presently
are attempting to elucidate the nature of the com-
pound(s) involved. Since the physiological role of the
5a-R-3a-HSD system in glial cells is largely un-
known, it is difficult to speculate on the biological
significance of a neuronal mechanism that stimulates
the metabolism of steroid hormones in A1 cells. How-
ever, one should recall that the formation of DHT is a
mechanism for potentiating androgenic actions, while
the subsequent conversion to 3a-diol is a mechanism
of steroid catabolism, since 3a-diol is much less ef-
fective than T as an androgen and does not bind to the
androgen receptor (for review, see Celotti et al., 1992;
Martini, 1982). Consequently, neuronal influences on
A1 cells may increase (by acting on the 5a-R), or
decrease (by acting on the 3a-HSD), the androgenic
potential of circulating T. However, the physiological
meaning of this phenomenon remains to be estab-
lished.
The same coculture system and transfer of CM of
A1 have been used to analyze the possible effects of
astrocytic secretions on a neuronal cell line, the
GT1-1 cells, which synthesize and secrete LHRH.
This cell line derives from a hypothalamic LHRH-
producing tumor, induced by genetically targeted tu-
morigenesis in a female transgenic mouse. We have
found that CM of A1 mimics the effect of coculture in
that it strongly stimulates the release of LHRH from
GT1-1 cells (Melcangi et al., 1995b). TGFb appears
to be the putative secreted factor that astrocytes re-
lease to induce LHRH secretion, since the activity of
CM of A1 is fully antagonized by a TGFb-neutraliz-
ing antibody. Moreover, direct exposure to TGFb1,
like the addition of CM of A1, stimulates LHRH
release from GT1-1 cells (Melcangi et al., 1995b). In
parallel experiments, it was shown that TGFb1, as
well as CM of A1, also modifies LHRH gene expres-
sion in GT1-1 cells (Galbiati et al., 1996). GT1-1 cells
also appear to be steroid sensitive since they express
receptors for estrogens, androgens, progestins, and
corticosteroids (Poletti et al., 1994; Chandran et al.,
1994; for review, see Herbison, 1998) and also pos-
sess 5a-R and 3a-HSD activities (Poletti et al., 1994;
Melcangi et al., 1997b). Consequently, A1 in a cocul-
ture system, might alter these enzymatic activities in
GT1-1 cells and modify the conversion of two possi-
ble substrates for this enzyme. When the conversion
of T and P was examined, we found that the presence
of A1 modifies 5a-R activity in GT1-1 cells. Surpris-
ingly, the effects observed were different depending
on the substrates used. Using T as the substrate, a
significant decrease of the formation of DHT was
apparent when GT1-1 cells were cocultured with A1.
When P was used as the substrate, a significant in-
crease in the formation of DHP was observed (Mel-
cangi et al., 1997b). These observations are intriguing
since they suggest that the substrate itself may influ-
ence 5a-R activity. The differential effects on the
formation of DHT and DHP cannot be explained on
the basis of an effect on either one of the two isoforms
of the 5a-R thus far cloned. In the authors’ opinion,
these data may be better explained by postulating the
existence of a third 5a-R isoform which has not yet
been cloned. Several other observations made re-
cently in this laboratory, both in vitro and in vivo,
support such a hypothesis. For example, pluripotential
CNS stem cells derived from mice striatum, when
induced in culture to differentiate into glial cells, start
forming DHT from T on the 14th day of differentia-
tion, whereas they start forming DHP from P on the
10th day of differentiation (Melcangi et al., 1996b).
The CM of C6 glioma and of 1321N1 human astro-
cytoma cell lines are unable to modify the formation
of DHT from T in A1, while inducing a statistically
significant decrease in the formation of DHP from P
in the same astrocytic cultures (Melcangi et al.,
1998b). The exposure of C6 cells to CM of rat fetal
neurons stimulates the formation DHT but not DHP
(Melcangi et al., 1998b). Furthermore, we recently
observed that castration decreases the formation of
DHT in the sciatic nerve of adult male rats but leaves
unmodified that of DHP (Magnaghi et al., submitted
for publication).
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PERIPHERAL NERVOUS SYSTEM
5a-R-3a-HSD Complex
It has been previously mentioned that in the CNS,
5a-R is present in elevated concentrations in white
matter (Melcangi et al. 1988a, 1989) as well as in
purified myelin membranes (Melcangi et al.,
1988a,b); central myelin membranes, however, do not
seem to possess 3a-HSD activity (Melcangi et al.,
1988a,b). To evaluate the possible presence of the
5a-R-3a-HSD complex in myelinated nerves of the
PNS, the metabolism of T into its 5a-reduced metab-
olites was evaluated in the sciatic nerve of adult male
rats, a myelinated peripheral sensorimotor nerve. The
study has shown that there is a conspicuous metabo-
lism of T in sciatic nerve. The formation of DHT was
at least equal to that found in central white matter and
higher than that found in the cerebral cortex (Melca-
ngi et al., 1990b, 1992). Moreover, in contrast to the
low production of 3a-diol in the CNS (Melcangi et
al., 1988a), 3a-diol is produced in amounts similar to
those of DHT in the sciatic nerve (Melcangi et al.,
1990b, 1992). To the authors’ knowledge, until these
data were published, no information was available on
the uptake and metabolism of testosterone in periph-
eral nerves, which had never been considered as pos-
sible target structures for androgenic steroids and,
more generally, for hormonal steroids. On the basis of
these preliminary observations, it was suggested that
also the PNS might be included among steroid-sensi-
tive target structures. Recent findings that mRNA for
AR is present in male rat sciatic nerve extracts support
this assumption (Melcangi et al., 1998a). In this con-
text, it is necessary to underline once more that the
5a-R also metabolizes P and corticosteroids (for re-
view, see Celotti et al., 1992). It remains to be ascer-
tained which of these three families of steroids (an-
drogens, progestins, and/or corticosteroids) represents
the physiological substrate for the 5a-R-3a-HSD
complex in sciatic nerve. The observation that 3a-diol
is formed with considerable yields in sciatic nerve is
surprising on the basis of observations previously
reported (Melcangi et al., 1990b, 1992) that this me-
tabolite is completely absent in purified CNS myelin.
The high peripheral production of 3a-diol might be
explained by the fact that the peripheral myelin differs
metabolically from its central counterpart; this is cer-
tainly supported by the finding that the peripheral
myelin has a biochemical composition different from
that of the brain (see below).
An additional clear-cut difference between central
and peripheral myelin was encountered when animals
of different age were studied. There was an age-
related drop of 5a-R activity in peripheral nerves,
while 5a-R was unaffected by age in the CNS, (Mel-
cangi et al., 1990b, 1992).
ROLE OF STEROIDS AND EFFECT OF
AGING ON PERIPHERAL MYELIN
Old and recent morphological observations indicate
that in aged mammals, the axons of large myelinated
fibers of the PNS undergo atrophy and their myelin
sheaths increase in thickness, develop irregularities
(Thomas et al., 1980; Grover-Johnson and Spencer,
1981; Johansson et al., 1996), and show the appear-
ance of bubbles (Grover-Johnson and Spencer, 1981;
Spencer and Thomas, 1970) and of adaxonal Schwann
cell protrusions, a process through which Schwann
cells remove debris from the axoplasm (Spencer and
Thomas, 1974). Furthermore, the ratio between nodal
spacing and fiber diameter increases and signs of
Wallerian degeneration may occur (Thomas et al.,
1980). In peripheral nerves of aged rats, dogs, cats
(Adinolfi et al., 1991; Chase et al., 1992; Morales et
al., 1987), and humans (Downie and Newell, 1961;
Mayer, 1963), these age-related morphological
changes indicate segmental demyelination and are
associated with a functional deterioration and a de-
creased velocity of conduction (Adinolfi et al., 1991;
Chase et al., 1992; Morales et al., 1987; Downie and
Newell, 1961; Mayer, 1963). Surprisingly, there are
no data to show whether aging affects gene expression
and synthesis of myelin-related proteins such as the
glycoprotein Po (Po), MBP, and peripheral myelin
protein 22 (PMP22) in peripheral nerve. Po (for re-
view, see Spiryda, 1998) is the most abundant protein
of the peripheral myelin (about 50% of the total) in
several animal species including humans (Isaque et al.
1980). This protein is a specific product of Schwann
cells (Brockes et al., 1980), and is consequently ab-
sent in the CNS (Kitamura et al., 1976). Po is con-
sidered an integral membrane protein and may be
glycosylated (Kitamura et al., 1976; Everly et al.,
1973; Roomi et al., 1978), phosphorylated (Singh and
Spritz, 1976; Wiggins and Morell, 1980), sulfated
(Matthieu et al., 1975), and acylated (Agrawal et al.,
1983; Sakamoto et al., 1986). The protein is thought
to play an important physiological role in the main-
tenance of the multilamellar structure of PNS myelin
(D’Urso et al., 1990), serving to link adjacent lamel-
lae via homophyllic binding of Po on extracellular
surfaces, and thereby stabilizing the assembly of com-
pact myelin (Lemke, 1986; Snipes and Suter, 1995).
MBP, the second most abundant protein in the PNS
(Stahl et al., 1990), is localized at the cytoplasm
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apposition of myelin lamellae (the major dense line),
and is also believed to be important for myelin com-
paction at this surface (Campagnoni and Macklin,
1988; Lemke, 1986; Snipes and Suter, 1995). PMP22
represents 2–5% of the peripheral myelin in rodents
and humans (Pareek et al., 1993). The pattern of
expression of this protein is synchronous with myelin
formation; the protein appears almost exclusively in
the compact sheath, where it is involved in regulating
myelin stability (Snipes et al., 1992; Kuhn et al.,
1993; Zoidl et al., 1995).
Given that little is known about the effects of aging
on myelin gene expression in perpheral nerve, we
analyzed whether the process of aging might be as-
sociated with measurable modifications of Po, MBP,
and PMP22 gene expression in the sciatic nerve of the
male rat. Because of the presence of PR in Schwann
cells (Jung-Testas et al., 1996; Magnaghi et al., 1999),
we also analyzed whether physiological progesta-
tional agents such as P and its 5a-reduced metabolites
could modulate, when given in vivo to aged rats, the
levels of Po, MBP, and PMP22 mRNA. Finally, we
tested whether these steroids might influence Po and
PMP22 gene expression in 3- to 4-month-old adult
rats and in Schwann cell cultures obtained from the
sciatic nerve of neonatal rats. Because of the presence
of AR in the sciatic nerve (Magnaghi et al., 1999), a
few experiments were performed using T and its
5a-reduced metabolite, DHT. Using in situ hybridiza-
tion and/or Northern blot analysis, we found that
mRNAs for Po, MBP, and PMP22 were strongly
decreased (about 75%) in the sciatic nerves of aged
(22- to 24-month-old) male rats compared to the sci-
atic nerve of 3-month-old male rats (Melcangi et al.,
1998c, 1999). These observations provide a possible
explanation for the several morphological and func-
tional changes seen in peripheral nerves of aged ani-
mals (Thomas et al., 1980; Grover-Johnson and Spen-
cer, 1981; Johansson et al., 1986; Spencer and
Thomas, 1970; Adinolfi et al., 1991; Chase et al.,
1992; Morales et al., 1987; Downie and Newell, 1961;
Mayer, 1963).
The subsequent experiment was designed to inves-
tigate whether systemic administration of P, DHP, and
THP counteracts the drop in mRNA levels of Po,
MBP, and PMP22 in aged animals. The results indi-
cate that P induces in the sciatic nerve of aged rats a
slight increase in Po gene expression. DHP, on the
other hand, significantly increases the level of Po
mRNA, an effect not duplicated by THP (Melcangi et
al., 1998c, 1999). Subsequent experiments have indi-
cated that in the sciatic nerve of male rats, not only Po
mRNA levels, but also the levels of Po protein de-
crease with age (Melcangi et al., 1998d); as in the case
of Po gene expression, treatment with DHP proved
effective in increasing the levels of Po protein in aged
animals (Melcangi et al., 1998d). The fact that P and
not DHP was very poorly active in inducing an in-
crease of Po gene expression deserves some consid-
eration. Since the 5a-R activity in the whole sciatic
nerve decreases significantly during aging (Melcangi
et al., 1990b, 1992), very little DHP could actually be
formed from P in the aged animals. The effect of
steroids on Po gene expression seems to be specific
for progestins, since androgens, like T and its 5a-
reduced metabolite DHT, were ineffective (Melcangi
et al., 1998d). Moreover, P, DHP, and THP had no
effect on the expression of MBP and PMP22 genes in
aged rats (Melcangi et al., 1998c, 1999).
Subsequent experiments were performed to ana-
lyze whether P, DHP, and THP affect Po and PMP22
gene expression in normal adult animals (3–4 months
old) rather than in old animals. P, DHP, and THP
were all able to increase Po mRNA levels above the
levels present in untreated normal controls. From a
quantitative point of view, DHP appeared to be more
effective than the other two steroids (Melcangi et al.,
1999). Like with old animals, P and DHP were inef-
fective in changing PMP22 mRNA levels in the sci-
atic nerve of adult male rats. Unexpectedly, THP was
extremely effective in increasing PMP22 mRNA lev-
els (Melcangi et al., 1999). The discrepancy between
THP in adult and aged animals with regard to Po and
PMP22 gene expression deserves some discussion.
Since THP may act via the GABAergic system, the
possibility exists that GABAA receptors might be
involved in the control of these two proteins in the
sciatic nerve. One hypothesis which may easily ex-
plain why THP had no effect in old animals is that
GABAA receptors in the PNS decrease with advanc-
ing age. Unfortunately, no data are available to sub-
stantiate this hypothesis. However, it is important to
remember that a decrease of GABA binding (Dalezios
and Matsokis, 1998) and of GABAA receptor subunit
mRNAs (Gutierrez et al., 1997) has been observed in
the CNS of aged animals. Experiments are in progress
in our laboratory to ascertain whether the in vivo
activity of the GABAA receptors declines or disap-
pears with age in the PNS.
The effect of P, DHP, and THP in the control of
peripheral myelin gene expression (with particular
attention to Po and PMP22) has also been established
in in vitro experiments using cultures of rat Schwann
cells. Within 2 h, P and DHP induced a significant
increase of Po gene expression. This effect decreased
at later intervals (6 h). There was no effect on PMP22
gene expression of either steroid. However, THP
proved very effective in stimulating both Po and
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PMP22 gene expression in cultured Schwann cells
(Melcangi et al., 1998c, 1999). The responses to ste-
roids by cultured Schwann cells appeared to be iden-
tical to those observed in vivo in adult animals. It is
possible that P, DHP, and THP act via different mech-
anisms. Because P and DHP bind to the PR, their
effect might be due to the activation of classical
progesterone responsive element (PRE) (Rupprecht et
al., 1993, 1996). In contrast, THP does not interact
with PR, but is a potent agonist for the GABAA
receptor (Celotti et al., 1992). Because of this possi-
bility, reverse transcriptase–polymerase chain reac-
tion (RT-PCR) was used to determine whether sub-
units of the GABAA receptor are expressed in the
sciatic nerve and in cultured Schwann cells. Primer
pairs specific for the rat subunit subtypes a1, a2, a3,
a6, b1, b2, b3, g1, g2L, and g2S were used. The
major bands found in the sciatic nerve of adult male
rats were those of a2, a3, b1, b2, and b3. Cultured
Schwann cells showed a similar pattern of expression
of GABAA subunit mRNAs, although with different
band intensities. The RT-PCR products were con-
firmed by sequencing, and the results indicated 100%
identity with mRNA sequences of a3 (a.n. X51991),
b1(a.n. X15466), b2 (a.n. X15467), and b3 (a.n.
U14420), and 97% homology for a2 (a.n. L08491)
(Melcangi et al., 1999). The presence of GABAA
receptor subunits in the sciatic nerve and cultured
Schwann cells raises the possibility that the effects of
THP on Po and PMP22 gene expression are due to an
effect of the steroid on this neurotransmitter receptor
system. The situation, however, may be different for
these two proteins. Keeping in mind that both DHP
and THP increase Po gene expression, whereas only
THP increases PMP22 gene expression, and that the
sciatic nerve and Schwann cells possess the enzyme
3a-HSD, which is bidirectional, we propose that THP
might be retroconverted to DHP and bind to the PR.
An effect of P, DHP, and THP through the PR is
certainly supported by the results of a computer anal-
ysis we recently performed which identified more
than one putative progesterone responsive elements in
the Po promoter region (Magnaghi et al., 1999). In the
control of Po gene expression, the classical mode of
action, by interaction to PR, may prevail over the
GABAergic mechanism. A similar explanation cannot
apply to the effect of THP on PMP22 gene expres-
sion, since DHP was ineffective on the expression of
this gene (Melcangi et al., 1999). Consequently, a
GABAergic mechanism may be the mode of action
for THP on PMP22 gene expression. However, De´-
sarnaud et al. (1998), using a different experimental
setup (Schwann cells transiently transfected with a
reporter construct), found that P stimulates the expres-
sion of the PMP22 gene acting on promoter 1, but not
promoter 2. Reasons for this discrepancy may reside
in the differences between the two experimental mod-
els used.
In conclusion, the present data show that the gene
expression of two important proteins of the peripheral
myelin (PMP22 and Po) can be influenced by proges-
terone derivatives. The hypothesis has been put for-
ward that part of the hormonal effects might occur not
through the classical PR, but rather via an interaction
with the GABAA receptor. In particular, hormonal
regulation of Po gene expression might be via the PR,
whereas expression of PMP22 gene might be con-
trolled by progestagen activity via an interaction with
the GABAergic system. Use of molecules that interact
with either the PR or the GABAA receptor may serve
as new therapeutic approaches in demyelinating dis-
eases that are characterized by alterations in Po or
PMP22 synthesis, respectively. Experiments are cur-
rently in progress to confirm this hypothesis.
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